Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Boston Scientific Reveals FDA Nod, Launch Of INGENIO, ADVANTIO & INVIVE CRT-P

Boston Scientific Corp. (BSX: Quote) unveiled FDA approval and market launch of its INGENIO and ADVANTIO pacemakers and INVIVE cardiac resynchronization therapy pacemakers, or CRT-P.

The INGENIO and ADVANTIO pacemakers feature RightRate pacing technology designed to treat chronotropic incompetence, or CI. CI is the inability of the heart to regulate its rate appropriately in response to physical activity, which may cause patients to feel tired or short of breath during daily activities such as walking or climbing stairs. The company noted that the first implant of the INGENIO pacemaker in the U.S. was performed on May 3 by Bruce Wilkoff, Director of Cardiac Pacing and Tachyarrhythmia Devices at the Cleveland Clinic.

In addition to RightRate, the INGENIO pacemaker offers Respiratory Rate Trend, or RRT, an exclusive feature that monitors respiration, a key vital sign. The INVIVE CRT-P offers RRT as part of HF Perspectiv, a comprehensive suite of heart failure diagnostics designed to provide health care professionals with additional information to guide treatment decisions.

The INGENIO, ADVANTIO and INVIVE devices are designed for use with Boston Scientific's new LATITUDE NXT Remote Patient Management system, which is currently under review by the FDA, and will enable physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status.

Register
To receive FREE breaking news email alerts for Boston Scientific Corp and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Global consumer confidence increased in the second quarter to reach the highest levels since the first quarter in 2007 as job optimism improved, results of a survey by Nielsen showed Tuesday. The Nielsen Global Consumer Confidence Index rose a point from the previous quarter to 97 in the second quarter.... Texas Instruments Inc., the world's largest maker of analog chips, said Monday after the markets closed that its second quarter profit rose 3% from last year, as revenue increased 8%. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave an upbeat outlook for the third quarter. After coming under pressure in early trading on Monday, stocks regained some ground over the course of the trading session but still closed modestly lower. The pullback on the day partly offset the strength that was seen last week.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.